These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6221010)

  • 21. In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim.
    Digranes A; Dibb WL; Benonisen E
    Chemotherapy; 1985; 31(6):466-71. PubMed ID: 2934234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative evaluation of norfloxacin and cinoxacin in the therapy of complicated infections of the urinary tract].
    Cristiano P; Morelli G; Simioli F; Iovene MR; Della Vittoria Scarpati M; Manguso L
    Minerva Med; 1989 Apr; 80(4):393-5. PubMed ID: 2657499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antibacterial activity of norfloxacin and pipemidic acid in a randomized double-blind study].
    Zerqueni G; Rocca Rossetti S
    Minerva Urol Nefrol; 1984; 36(3):247-51. PubMed ID: 6241966
    [No Abstract]   [Full Text] [Related]  

  • 24. Antibacterial activity of norfloxacin.
    Norrby SR; Jonsson M
    Antimicrob Agents Chemother; 1983 Jan; 23(1):15-8. PubMed ID: 6219617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens.
    Digranes A; Dibb WL; Ostervold B
    Acta Pathol Microbiol Immunol Scand B; 1984 Apr; 92(2):101-6. PubMed ID: 6233841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of norfloxacin in synthetic media and human urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid.
    Shah PM; Ottnad-Walz M; Stille W
    Methods Find Exp Clin Pharmacol; 1983 Dec; 5(10):731-4. PubMed ID: 6231438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections--a multi-centre trial.
    Watt B; Chait I; Kelsey MC; Newsom SW; Newsom RA; Smith J; Toase PD; Deaney NB; Round EM; Vogel R
    J Antimicrob Chemother; 1984 May; 13 Suppl B():89-94. PubMed ID: 6234281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Ullmann U
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Occurrence of gram negative bacteria in midstream bladder urine and their sensitivity to quinoline derivatives.
    Esposito S; Galante D; Pennucci C; Barba D
    Microbiologica; 1985 Jul; 8(3):269-76. PubMed ID: 3162081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of simple urinary tract infections in general practice with a 3-day course of norfloxacin.
    Kirby CP
    J Antimicrob Chemother; 1984 May; 13 Suppl B():107-12. PubMed ID: 6234270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative "in vitro" activity of ciprofloxacin (Bay o9867) and other antimicrobial agents against urinary bacterial isolates.
    Piccolomini R; Ravagnan G
    Chemioterapia; 1986 Aug; 5(4):249-56. PubMed ID: 3769047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections.
    Vogel R; Deaney NB; Round EM; VandenBurg MJ; Currie WJ
    J Antimicrob Chemother; 1984 May; 13 Suppl B():113-20. PubMed ID: 6234271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility of Bordetella pertussis to doxycycline, cinoxacin, nalidixic acid, norfloxacin, imipenem, mecillinam and rifampicin.
    Zackrisson G; Brorson JE; Björnegård B; Trollfors B
    J Antimicrob Chemother; 1985 May; 15(5):629-32. PubMed ID: 2861190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.
    Downs J; Andriole VT; Ryan JL
    Antimicrob Agents Chemother; 1982 Apr; 21(4):670-2. PubMed ID: 6211142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.
    Gadebusch HH; Shungu DL; Weinberg E; Chung SK
    Infection; 1982 Jan; 10(1):41-4. PubMed ID: 6461606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [In vitro comparative activity of norfloxacin in the comparison of pathogenic bacteria of the urinary tract].
    Carlone NA; Cuffini AM; Tullio V; Savoia D; Cavallo GP
    G Batteriol Virol Immunol; 1986; 79(1-6):85-97. PubMed ID: 3479370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
    Reeves DS; Bywater MJ; Holt HA; White LO
    J Antimicrob Chemother; 1984 Apr; 13(4):333-46. PubMed ID: 6233250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative in vitro activity of norfloxacin against urinary tract pathogens.
    Haase D; Urias B; Harding G; Ronald A
    Eur J Clin Microbiol; 1983 Jun; 2(3):235-41. PubMed ID: 6224679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro synergistic activity of some chinolinic compounds combined with beta-lactam antibiotics against gram-positive and gram-negative clinical isolates.
    Ravagnan G; Piccolomini R; Speciale AM; Russo G; Renzini G
    Chemotherapy; 1985; 31(3):191-9. PubMed ID: 3996087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.